Document is current

Article History

Received: 1 June 2019

Accepted: 30 July 2019

First Online: 29 August 2019

Ethics approval and consent to participate

: Induced pluripotent stem cells used for astroglia differentiation in this study were derived with written informed consent by the donors or their parents. AF hiPSC generation was approved by the Ethics Committee of the Medical Faculty, University of Bonn (permit# 275/08). C9 hiPSC generation was approved by the Ethics Review Board, Stockholm (Registration number: 2012/208–31/3). C1 hiPSC generation was approved by the regional ethical committee of Uppsala, Sweden (D-number 319/2009). R-hiPSC1j were generated from BJ fibroblast (CRL-2522) purchased from ATCC, Manassas, Virginia, USA, in compliance with the ATCC materials transfer agreement. The ethical consent form was requested from ATCC but was not available. As such, the generation of hiPSC from the BJ fibroblast line was reviewed and supported by the AstraZeneca Human Biological Sample Governance Team.

: Not applicable.

: The authors indicate no potential competing interests. Ryan Hicks is employed by AstraZeneca. Therése Kallur is employed by BioLamina. Henrik Zetterberg has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (unrelated to the submitted work).